New Launch15 Dec 2025, 08:34 am
Biocon Limited launches GLP-1, Liraglutide, in the Netherlands
AI Summary
Biocon Limited, an innovation-led global biopharmaceutical company, announced the launch of its GLP-1 peptide, Liraglutide, for diabetes and obesity in the Netherlands. The drug-device combination will be marketed under the brand names Diavorin® for diabetes and Vobexoryn® for chronic weight management. This launch marks the first country in the European Union where the Company will directly launch Liraglutide under its own brand.
Key Highlights
- Biocon Limited launches GLP-1, Liraglutide, in the Netherlands through its distribution partner Pharmamedic B.V.
- The drug-device combination will be marketed under the brand names Diavorin® for diabetes and Vobexoryn® for chronic weight management.
- This is the first country in the European Union where the Company will directly launch Liraglutide under its own brand.
- Liraglutide is a synthetic analog of GLP-1 peptide and is administered as a once-daily injection.
- Biocon Limited is an innovation-led global biopharmaceutical company committed to enhancing affordable access to complex therapies for chronic conditions.